Abstract
Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy. Registration study “TOURMALINE MM-1” was published in 2016. Nevertheless, clinical trials are significantly different from real-world use. From June 2016 to December 2018, IRd was available for Slovak patients with relapsed/refractory MM through a Named Patient Program. The aim of this study was to evaluate the efficacy and safety of ixazomib. We analyzed in this cohort study outcomes of 106 MM patients treated with IRd at 2 academic centers. The median age at diagnosis was 63 years (44–78). The median number of prior lines was 2 (1–7). The majority had high international staging system (ISS) score: 18, 29, and 59 were in the ISS I, ISS II, and ISS III groups, respectively. Treatment continued until progression, unacceptable toxicity, or death. The median follow-up for the entire cohort was 29 (0–49) months. The overall response rate was 74.5% (complete remission, 7.5%; partial remission, 67%). The median overall survival was not reached. Median progression-free survival (PFS) was 43 months (95% CI 35.6–50.4). The Kaplan–Meier method was used to generate survival curves, and we compared the influence of different factors on PFS. The most common hematological adverse events of any grade were neutropenia (90.4%), anemia (55.6%), and thrombocytopenia (43.4%). Our real-world data support the use of IRd as a highly effective and well-tolerated oral treatment protocol for relapsed myeloma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Research data are stored in an institutional repository and will be shared upon request to the corresponding author.
References
Parrondo RD, Alegria V, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S (2021) Ixazomib and lenalidomide maintenance therapy in multiple myeloma. Ann Hematol 100(3):851–853. https://doi.org/10.1007/s00277-020-04340-8
Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, Zhang W, Yang W, Li B, Fu C, Chen B, Hua L, Wang L, Luo J, Yang Y, Xu T, Wang W, Huang Y, Wu G, Liu P (2020) Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol 99(11):2589–2598. https://doi.org/10.1007/s00277-020-04234-9
Röllig C, Knop S, Bornhäuser M (2015) Multiple myeloma. Lancet 385(9983):2197–208. https://doi.org/10.1016/S0140-6736(14)60493-1
Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S (2019) Role of proteasome inhibitors in relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 19(1):9–22. https://doi.org/10.1016/j.clml.2018.08.016
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–34. https://doi.org/10.1056/NEJMoa1516282
Mansournia MA, Higgins JP, Sterne JA, Hernán MA (2017) Biases in randomized trials: a conversation between trialists and epidemiologists. Epidemiology 28(1):54–59. https://doi.org/10.1097/EDE.0000000000000564
Ramagopalan SV, Simpson A, Sammon C (2020) Can real-world data really replace randomised clinical trials? BMC Med 18(1):13. https://doi.org/10.1186/s12916-019-1481-8
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420. https://doi.org/10.1200/JCO.2005.04.242
Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60. Accessed June 21, 2021
Smolewski P, Rydygier D (2019) Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opin Investig Drugs 28(5):421–433. https://doi.org/10.1080/13543784.2019.1596258
Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10:217–226. https://doi.org/10.2147/DDDT.S93602
Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970–1980. https://doi.org/10.1158/0008-5472.CAN-09-2766
Funding
The study was supported by grants VEGA 1/0187/17 and APVV-17–0054.
Author information
Authors and Affiliations
Contributions
All authors drafted and reviewed the manuscript, approved the final version, and decided to publish this report, and they vouch for data accuracy and completeness. JSO, TG, JC, MH, NS, LV, and MK participated in the conception and study design, acquired data, and contributed to the analysis and interpretation of results. JSO and JS contributed to the writing of the final version of the manuscript.
Corresponding author
Ethics declarations
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all participants included in the study.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sokol, J., Guman, T., Chudej, J. et al. Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma. Ann Hematol 101, 81–89 (2022). https://doi.org/10.1007/s00277-021-04663-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04663-0